Nanoviricides Inc (NNVC) Stock Price, Quote & News

Company Profile

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-...

Industry: Biotechnology

Sector: Healthcare

Phone: 203 937 6137

Website: www.nanoviricides.com

Address:

1 Controls Drive, Shelton, United States

STRAYNUT Jul. 7 at 10:10 PM

$NNVC Broad-Spectrum NV-387 To Enable Emperic Antiviral Treatment - A Revolutionary Prospect Reminiscent of Antibiotics June 24, 2025https://www.nanoviricides.com/files/News%20PDFs/Broad-Spectrum%20NV-387%20To%20Enable%20Emperic%20Antiviral%20Treatment%20-%20A%20Revolutionary%20Prospect%20Reminisc.pdf

0 · Reply

tomzprofit Jul. 7 at 7:26 PM

$NNVC Phase 1 paperwork in process with FDA. Trials aren't required to be done in US.

1 · Reply

ThaDreadPirate Jul. 7 at 6:52 PM

$NNVC this is the all-time stock performance. Destroying shareholder value by dodging US FDA clinical trials for 20 years!

0 · Reply

ThaDreadPirate Jul. 7 at 6:48 PM

$NNVC has never conducted a clinical trial per clinicaltrials.gov so if a bagholder wants to prove me wrong, please provide the clinicaltrials.gov link that disproves my statement. Circumventing the U.S. FDA in conducting clinical trials is a major red flag!!! You can get away with anything in Africa, unfortunately.

0 · Reply

HotStockNews Jul. 7 at 6:40 PM

$NNVC

0 · Reply

HotStockNews Jul. 7 at 6:37 PM

NYSEAMERICAN: $NNVC Trying To Break $1.50 next target $2.79, Strong Buying Area🔥 ⚡️Targets $10B+ market across viral diseases. ⚡️MPox trial in Africa = low cost + fast data. ⚡️Potential BARDA/government contracts (e.g. $150M+ for rivals).

0 · Reply

ThaDreadPirate Jul. 7 at 6:35 PM

$NNVC loses $8 million per year and currently has less than $1 million in cash. Anyone who says they have enough cash to last until February is lying to you and is unable to perform 1st grade elementary school math. These are facts whether you like them or not. Dilution is imminent and will occur below $1.00 per share.

0 · Reply

tomzprofit Jul. 7 at 6:03 PM

$NNVC TDA doesn't know the difference between a vaccine and a drug.

0 · Reply

tomzprofit Jul. 7 at 5:59 PM

$NNVC Nanoviricides has a shelf offering for stock as a CONTINGENCY. They have no plans to use it at this time. They have sufficient funds for operating expenses and expenses for Phase 2 through February 2026. If NV 387 is successful against monkey pox, the WHO will permit NNVC to sell NV 387 in regions and countries where monkey pox is a health threat. Don't let the liars on this forum discourage you from increasing your positions.

0 · Reply

tomzprofit Jul. 7 at 5:44 PM

$NNVC NV 387 completed Phase 1 in India in April 2024 with no dropouts and minimal side effects. The HUMAN subjects were not infected per the protocol as agreed upon by the FDA. Phase 2 has been initiated in the Congo targeting monkey pox. No drug has yet been administered. The post stating no human has received NV 387 in wrong, either a liar or a fool, probably both.

1 · Reply

With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan

Jun 4, 2025, 6:55 AM EDT - 4 weeks ago

NanoViricides Measles Drug Development Animal Study is Imminent

May 28, 2025, 6:30 AM EDT - 5 weeks ago

NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025

May 22, 2025, 6:30 AM EDT - 6 weeks ago

The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan

May 14, 2025, 6:30 AM EDT - 7 weeks ago

Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution

May 5, 2025, 6:30 AM EDT - 2 months ago

NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC

Apr 29, 2025, 6:30 AM EDT - 2 months ago

Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It

Apr 14, 2025, 6:30 AM EDT - 3 months ago

Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak

Mar 11, 2025, 6:30 AM EDT - 4 months ago

NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company

Mar 4, 2025, 6:30 AM EST - 4 months ago

Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan

Feb 19, 2025, 6:30 AM EST - 4 months ago

NanoViricides, Inc. Has Filed its Quarterly Report

Feb 11, 2025, 6:30 AM EST - 5 months ago

NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape

Jan 29, 2025, 6:30 AM EST - 5 months ago

NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025

Jan 27, 2025, 6:30 AM EST - 5 months ago

NanoViricides Engages CRO for Phase II Clinical Trial

Jan 13, 2025, 6:30 AM EST - 6 months ago

NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025

Jan 8, 2025, 6:30 AM EST - 6 months ago

Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals

Dec 23, 2024, 6:30 AM EST - 7 months ago

NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape

Nov 15, 2024, 6:30 AM EST - 8 months ago

NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID

Nov 4, 2024, 12:00 AM EST - 8 months ago

NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am

Oct 22, 2024, 6:30 AM EDT - 9 months ago

NanoViricides President Dr. Diwan to Present at the PODD Conference

Oct 15, 2024, 6:30 AM EDT - 9 months ago

NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology

Oct 8, 2024, 6:30 AM EDT - 9 months ago

NanoViricides to Present at the Global AMR Summit 2024 Tomorrow

Sep 30, 2024, 6:30 AM EDT - 10 months ago

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID

Sep 26, 2024, 6:30 AM EDT - 10 months ago

NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” Drugs

Aug 26, 2024, 7:30 AM EDT - 11 months ago

MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX

Aug 19, 2024, 6:30 AM EDT - 11 months ago

NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 - A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections

Aug 8, 2024, 6:30 AM EDT - 11 months ago

NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics

Aug 2, 2024, 7:00 AM EDT - 1 year ago

Can Nanotechnology offer Better Solutions for COVID, RSV and other Viruses?

Aug 1, 2024, 6:30 AM EDT - 1 year ago

"NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy"; "Novel Anti-Viral Could Boost a US$3 Billion Market" - Conclude Two Independent Research Reports on NanoViricides

Jul 24, 2024, 6:30 AM EDT - 1 year ago

COVID is Here to Stay and NV-387 is a Much Needed Drug Against It, Reminds NanoViricides

Jul 11, 2024, 6:30 AM EDT - 1 year ago

A Single Drug Against Multiple Respiratory Virus Infections - COVID, RSV, Influenza, Bird Flu - Planning Next Phase of Clinical Trials, Says NanoViricides

Jun 24, 2024, 6:00 AM EDT - 1 year ago

A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides

Jun 20, 2024, 6:30 AM EDT - 1 year ago

A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model

Jun 11, 2024, 6:30 AM EDT - 1 year ago

Orally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect

Jun 4, 2024, 6:30 AM EDT - 1 year ago

The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect

May 20, 2024, 6:30 AM EDT - 1 year ago

Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential Cure

May 15, 2024, 6:30 AM EDT - 1 year ago

NanoViricides Has Filed its Quarterly Report

May 14, 2024, 6:30 AM EDT - 1 year ago

A Novel Broad-Spectrum Antiviral with Activity Against RSV

May 10, 2024, 6:30 AM EDT - 1 year ago

NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City

May 8, 2024, 6:30 AM EDT - 1 year ago

A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox

May 6, 2024, 6:30 AM EDT - 1 year ago

A Novel Broad-Spectrum Antiviral with Activity Against Influenza A

Apr 30, 2024, 6:30 AM EDT - 1 year ago

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon

Feb 15, 2024, 6:30 AM EST - 1 year ago

NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon

Feb 1, 2024, 6:20 AM EST - 1 year ago

Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics

Jan 29, 2024, 6:30 AM EST - 1 year ago

Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found

Jan 4, 2024, 6:30 AM EST - 1 year ago

NanoViricides to Present at the Biotech Showcase in San Fransisco

Nov 28, 2023, 6:40 AM EST - 1 year ago

The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company's Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides

Nov 15, 2023, 6:45 AM EST - 1 year ago

NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications

Nov 14, 2023, 6:45 AM EST - 1 year ago

Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development

Oct 16, 2023, 6:45 AM EDT - 1 year ago

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV

STRAYNUT Jul. 7 at 10:10 PM

0 · Reply

tomzprofit Jul. 7 at 7:26 PM

$NNVC Phase 1 paperwork in process with FDA. Trials aren't required to be done in US.

1 · Reply

ThaDreadPirate Jul. 7 at 6:52 PM

$NNVC this is the all-time stock performance. Destroying shareholder value by dodging US FDA clinical trials for 20 years!

0 · Reply

ThaDreadPirate Jul. 7 at 6:48 PM

0 · Reply

HotStockNews Jul. 7 at 6:40 PM

$NNVC

0 · Reply

HotStockNews Jul. 7 at 6:37 PM

0 · Reply

ThaDreadPirate Jul. 7 at 6:35 PM

0 · Reply

tomzprofit Jul. 7 at 6:03 PM

$NNVC TDA doesn't know the difference between a vaccine and a drug.

0 · Reply

tomzprofit Jul. 7 at 5:59 PM

0 · Reply

tomzprofit Jul. 7 at 5:44 PM

1 · Reply

ThaDreadPirate Jul. 7 at 3:50 PM

Every bagholder must realize that $NNVC does NOT test their drugs in humans and never has since inception in 2005. When you don’t test in humans, you will never have a drug you can sell and the stock is destined to hit $0.00. This is reality.

0 · Reply

BullTradeFinder Jul. 7 at 3:36 PM

$NNVC Watch for a move to $1.76-$1.80 👀 Communicated-Disclaimer https://docs.google.com/document/d/12xGsph0k_UHA4vkSwkMqvagyFcx7_6i8J1y8kVX2zJE/edit?usp=sharing

0 · Reply

BullTradeFinder Jul. 7 at 2:39 PM

🚨 $NNVC is a sleeper biotech play with big upside • Novel “nanoviricide” platform • Targets deadly viruses: HIV, RSV, COVID, flu & more • Strong preclinical data One major update could send this flying. Communicated-Disclaimer https://docs.google.com/document/d/12xGsph0k_UHA4vkSwkMqvagyFcx7_6i8J1y8kVX2zJE/edit?usp=sharing

0 · Reply

Love1010 Jul. 3 at 2:03 AM

$NNVC someone knows about the dilution coming other than me?! Ha ha, big move down soon.

0 · Reply

ThaDreadPirate Jul. 2 at 7:37 PM

If all the $CVM and $GOVX bagholders want to pile into $NNVC before the upcoming imminent offering/ATM dilution, now is your chance. I know every bagholder likes to load up before horrible dilution hits! $GOVX -50% and $CVM -62%

1 · Reply

ThaDreadPirate Jul. 2 at 7:28 PM

I just walked into my local pet store and asked the manager if she was aware that all of her mice could get vaccinated for measles if she contacted $NNVC. She asked if I had a learning disability to which I replied, “No, I’m not a $NNVC bagholder.”

0 · Reply

ThaDreadPirate Jul. 2 at 7:21 PM

$NNVC never have I seen a biotech company be so passionate about vaccines for mice. Do all the bagholders own mice as pets? Because that’s all $NNVC does - they give vaccines to mice year after year after year. What a shame.

0 · Reply

ThaDreadPirate Jul. 2 at 7:14 PM

$NNVC this company started 20 years ago in 2005, and has yet to test any of their drug/vaccine candidates in any human. Get out now before you become the next bagholder.

0 · Reply

ThaDreadPirate Jul. 2 at 7:05 PM

$NNVC offering/ATM due in the next 3 weeks, possibly sooner. Price should steadily drop back to around $1.00 as investors anticipate dilution.

0 · Reply

STRAYNUT Jul. 1 at 11:36 AM

$NNVC There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/there-is-a-strong-business-case-for-phase-ii-clinical-program-for-tre-1044736

1 · Reply

BigSqueezeComing Jul. 1 at 11:17 AM

$NNVC There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate By ACCESSWIRE | July 01, 2025, 6:30 AM

0 · Reply

Love1010 Jun. 30 at 2:43 PM

$NNVC bearish monthly and quarterly candle forming. Once again, the uptrend has been squelched!

0 · Reply

Market Cap	22.18M
Revenue (ttm)	0.00
Net Income (ttm)	-8.29M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	178,900
Avg Vol	207,420
Day's Range	N/A - N/A
Shares Out	16.07M
Stochastic %K	74%
Beta	0.88
Analysts	Strong Sell
Price Target	$6.50